A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Overview
- Phase
- Phase 3
- Intervention
- SEP-4199 CR
- Conditions
- Depressive Episodes, Bipolar I Depression
- Sponsor
- Sumitomo Pharma America, Inc.
- Enrollment
- 64
- Locations
- 68
- Primary Endpoint
- Number of Subjects Who Experienced Adverse Events in Study
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression). Participants in the study will receive the drug being studied. This study is accepting male and female participants between 18 and 65 years old who have completed Study SEP380-301. This study will be conducted in approximately 90 study centers worldwide. The treatment duration for this study is one (1) year.
Detailed Description
This is a 12-month open-label safety extension study to evaluate the long-term safety, tolerability, and effectiveness of SEP-4199 CR 200-400 mg/day in the treatment of subjects with bipolar I depression who previously completed a lead-in study of SEP-4199 CR. The study will consist of a 12-month open-label flexible-dose treatment period, and a safety follow-up period. There are 15 scheduled visits, including a Baseline visit, 13 visits during the open-label treatment period, and 1 safety follow-up visit 7 (± 2) days after the last dose of study drug. If necessary, subjects may return to the clinic at anytime for an unscheduled visit
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.
- •Subject has completed 6 weeks of double-blind treatment and all scheduled assessments from Visit 6/EOT (Day 42) of the lead-in study of SEP-4199 CR.
- •Subject is medically appropriate for long-term open-label treatment with SEP-4199 CR in the opinion of the Investigator.
- •Female subjects of childbearing potential must agree to use effective and reliable contraception throughout the study and for at least 30 days after the last dose of study drug has been taken. In the Investigator's judgment, the subject will adhere to this requirement.
- •Male subjects agree to avoid fathering a child and to use effective methods of birth control throughout the study and until at least 90 days after the last study drug administration.
Exclusion Criteria
- •Subject is at high risk of non-compliance in the opinion of the Investigator.
- •Subject plans to initiate treatment with a prohibited psychotropic medication during the study.
- •Subject plans to initiate treatment with transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), vagus nerve stimulation (VNS), or deep brain stimulation (DBS) during the study.
- •Subject experienced a moderate or severe hyperprolactinemia-related AESI in the lead-in study of SEP-4199 CR.
- •Subject will require treatment with a drug that is associated with increases in QTc interval.
- •Subject had any of the following at Visit 6/EOT (Day 42) of the lead-in study of SEP-4199 CR based on machine reading:
- •increase in QTcF interval of ≥ 30 msec AND a QTcF interval ≥ 480 msec, from baseline of the lead-in study of SEP-4199 CR AND a QTCF interval ≥ 480msec
- •increase in QTcF interval ≥ 60 msec, from baseline of the lead-in study of SEP-4199 CR
- •QTcF interval ≥ 500 msec
- •treatment-emergent clinically significant ECG abnormality.
Arms & Interventions
SEP-4199 CR
SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily during open-label flexible-dose treatment period.
Intervention: SEP-4199 CR
Outcomes
Primary Outcomes
Number of Subjects Who Experienced Adverse Events in Study
Time Frame: 12 months
Incidence of adverse events
Number of Subjects Who Discontinued Due to Adverse Events
Time Frame: 12 months
Incidence of adverse events leading to discontinuation
Number of Subjects Who Experienced Serious Adverse Events in Study
Time Frame: 12 months
Incidence of Serious Adverse Events
Secondary Outcomes
- Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Change From Baseline(12 months)
- Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score - Change From Baseline(12 months)